All News

9 May 2007

MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV DiseaseAntibodies

8 May 2007

Peptech and Evogenix Merge to Form Antibody PowerhouseAntibodies

8 May 2007

Biolex Therapeutics Announces Agreement With Genmab For New Class Of AntibodiesAntibodies

8 May 2007

Abbott Seeks U.S. and E.U. Regulatory Approvals for HUMIRA(R) (Adalimumab) as a Treatment for Juvenile Rheumatoid ArthritisAntibodies

7 May 2007

Affitech Signs Antibody Research and Licensing Agreement with RocheAntibodies

5 May 2007

Viragen Shifts Development Focus for Anti-Cancer ProductsAntibodies

5 May 2007

Abbott’s Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis StudyAntibodies

4 May 2007

Data Presented at the American Academy on Neurology’s Annual Meeting Provide Update on Utilization and Safety of Tysabry(R) in Patients with Multiple SclerosisAntibodies

4 May 2007

Herceptin approved in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2 and hormone receptor-co-positive metastatic breast cancerAntibodies

3 May 2007

Y’s Therapeutics Initiates Phase II Trial With YSPSL in Liver Transplant Patients for Prevention of Ischemic Reperfusion (I/R) InjuryAntibodies

3 May 2007

ThromboGenics Announces Progress With its Pre-Clinical and Clinical ProgramsAntibodies

3 May 2007

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AANAntibodies

2 May 2007

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of NeurologyAntibodies

2 May 2007

Progenics Announces Positive Results in Clinical Trial of Novel HIV TherapyAntibodies

1 May 2007

Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients PublishedAntibodies

1 May 2007

Dr. Reddy’s launches Reditux(TM) Monoclonal Antibody Treatment for Non-Hodgkin’s LymphomaAntibodies

28 April 2007

CHMP Adopts Positive Opinion For Alexion’s Soliris(TM) In EuropeAntibodies

28 April 2007

Abbott’s HUMIRA(R) (adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn’s DiseaseAntibodies

27 April 2007

Royalty Pharma and InNexus Biotechnology Announce Agreement Regarding the Purchase of Royalty Rights Based on DXL(TM) Antibody ProductsAntibodies

27 April 2007

PDL BioPharma Advances Nuvion(R) Into Second Pivotal Study in Intravenous Steroid-Refractory Ulcerative ColitisAntibodies

25 April 2007

Y’s Therapeutics Completes Enrollment of Phase II Trial in the U.S. With YSPSL for Prevention of Delayed Graft Function in Renal TransplantationAntibodies

24 April 2007

KaloBios Licenses Humaneering(TM) Technology to Major Pharmaceutical CompanyAntibodies

24 April 2007

Micromet Achieves Milestone in BiTE(R) Research Collaboration with MedImmuneAntibodies

20 April 2007

MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE(R) MoleculeAntibodies

19 April 2007

Viventia Biotech generates novel human anti-cancer antibody, VB1-050, and identifies its novel targetAntibodies

19 April 2007

Anti-Cancer Agent Avastin(R), Approved in JapanAntibodies

18 April 2007

Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACRAntibodies

18 April 2007

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical StudiesAntibodies

18 April 2007

Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal ModelsAntibodies

17 April 2007

Data Presented at AACR Meeting Shows Peregrine’s Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer ModelsAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Aflibercept (Eylea) Biosimilars Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

TL1A Inhibitor Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

TROP-2-Targeted Immunotherapy Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review